Latham & Watkins Advises on Vir Biotechnology’s US$150 Million Public Offering of Common Stock
Vir Biotechnology (VIR) announced a US$150 million public offering of 15 million shares at US$10 each, with an option for 2.25 million more. Proceeds will go to the company, and closing is expected November 16, 2026. Latham & Watkins advised the underwriters.
How this was made

The 30-second read
Why it matters
The $150 M equity raise introduces significant dilution, likely pressuring the share price in the near term. Traders may consider short positions or hedges.
Market read
Primary disclosure of a large capital raise for a Nasdaq‑listed biotech, directly affecting VIR's share price.
What to watch
Potential strategic partnership or pipeline milestones that could be funded by the capital raise are not disclosed yet.
Background
Vir Biotechnology is a clinical‑stage biopharma focused on infectious diseases and cancer. The company is listed on Nasdaq under the ticker VIR.
Ticker impact
Vir Biotechnology announced pricing of a $150 million public offering of 15 million shares at $10 each, with a 30‑day option for 2.25 million additional shares.
likely pressure as the market prices in dilution from the $150 M capital raise
Large primary offering at $10 per share introduces new supply; investors typically react negatively to dilution unless proceeds fund a transformative catalyst.
Market effects
Biotech sector may see modest sell‑off as the raise highlights financing needs for clinical programs.
US biotech market could experience slight pressure, but impact is limited to the issuer.
Limited; primarily affects Vir Biotechnology and its investors.
Counterpoint
If the proceeds are deployed into high‑impact clinical trials, the long‑term upside could outweigh short‑term dilution concerns.
Key entities
- companyVir Biotechnology, Inc.
Issuer of the public offering.
- law_firmLatham & Watkins LLP
Advised the underwriters on the transaction.

